Verbascoside inhibits the epithelial‐mesenchymal transition of prostate cancer cells through high‐mobility group box 1/receptor for advanced glycation end‐products/ TGF ‐β pathway

Chun‐Hsien Wu,Chung‐Hsien Chen,Pei‐Fang Hsieh,Yen‐Hsi Lee,Wade Wei‐Ting Kuo,Richard Chen‐Yu Wu,Chih‐Hsin Hung,Yu‐Lin Yang,Victor C. Lin

DOI: https://doi.org/10.1002/tox.23107

IF: 4.109

2021-02-01

Environmental Toxicology

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction</h3><p>Prostate cancer has significant mortality and metastasis rate in the male. Unfortunately, effective treatment for patients with advanced prostate cancer is still lacking. Verbascoside, a phenylethanoid glycoside, displays various pharmacological properties, such as the anti‐cancer activities. The present study aimed to evaluate the effects of purified verbascoside on human prostate cancer and the associated molecular mechanisms.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Materials and Methods</h3><p>The human prostate cancer cell lines, Du‐145 and PC‐3, were treated with various concentrations of verbascoside (0.1, 1, 10 μM) for 24 h followed by the examination of cell viability using MTT and trypan blue exclusion assays. Cell migration and invasion capacities were assessed by wound healing assay and transwell system. Western blot and immunofluorescence staining were used to detect the expression of epithelial‐mesenchymal transition (EMT)‐associated factors, components of transforming growth factor (TGF‐β)/Smad signaling, and high‐mobility group box (HMGB)/receptor for advanced glycation end‐products (RAGE) axis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Verbascoside treatment significantly inhibited cell proliferation, migration, and invasion abilities of Du‐145 and PC‐3 cells. We showed that verbascoside decreased the expression of EMT promotors, Snail and Slug, and increased the expression of E‐cadherin. Moreover, the expression level of alpha‐smooth muscle actin was downregulated by verbascoside as well. Besides, we found that the TGF‐β pathway was suppressed, which was demonstrated by the diminished expression of type I and II TGF‐β receptors and phosphorylated Smad2/3 along with the upregulated Smad7. Our data suggested that this downregulation of TGF‐β signaling was mediated by repression of HMGB 1 (HMGB1)/RAGE axis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Verbascoside mitigated the cell proliferation and aggressiveness of prostate cancer via downregulation of TGF‐β‐associated EMT progression through HMGB1/RAGE suppression. Collectively, our findings revealed that verbascoside may be a beneficial dietary supplement for prostate cancer patients.</p></section>

toxicology,environmental sciences,water resources

What problem does this paper attempt to address?

This paper aims to explore and verify the effects of purified verbascoside (a phenylethanoid glycoside compound) on human prostate cancer cells and its related molecular mechanisms. Specifically, the study attempts to address the following issues:

1. **Inhibiting cell proliferation, migration and invasion abilities**: The study evaluated the effects of verbascoside on the cell viability, migration ability and invasion ability of two human prostate cancer cell lines (Du - 145 and PC - 3). The results showed that verbascoside significantly inhibited the proliferation, migration and invasion abilities of these two cell lines (Figure 1 and Figure 2).

2. **Inhibiting epithelial - mesenchymal transition (EMT)**: The study further explored the effects of verbascoside on the expression of EMT - related factors. The results indicated that verbascoside reduced the expressions of EMT - promoting factors Snail and Slug and increased the expression of E - cadherin. In addition, the expression of α - smooth muscle actin (α - SMA) was also down - regulated by verbascoside treatment (Figure 3).

3. **Inhibiting TGF - β signaling pathway**: The study also evaluated the effects of verbascoside on the TGF - β signaling pathway. The results found that verbascoside inhibited the expressions of TGF - β receptor type I and type II, reduced the levels of phosphorylated Smad2/3, and increased the expression of Smad7 (Figure 4). These changes suggest that verbascoside affects the EMT process by inhibiting the TGF - β signaling pathway.

4. **Inhibiting HMGB1/RAGE axis**: The study further explored the effects of verbascoside on the expressions of high - mobility group box 1 (HMGB1) and its receptor RAGE. The results showed that verbascoside dose - dependently decreased the protein and mRNA expressions of HMGB1 and RAGE (Figure 5). These results suggest that verbascoside may inhibit the TGF - β signaling pathway by inhibiting the HMGB1/RAGE axis, thereby affecting the EMT process.

In summary, the main purpose of this study was to evaluate the effect of verbascoside in inhibiting the proliferation, migration and invasion abilities of prostate cancer cells and to reveal its molecular mechanism of affecting the EMT process by inhibiting the HMGB1/RAGE axis and the TGF - β signaling pathway. These findings suggest that verbascoside may be a beneficial dietary supplement and help slow down the progression of prostate cancer.